Rapamycin: one drug, many effects
By Jing Li, Sang Gyun Kim, J. Blenis. Cell Metabolism, 2014
1,157 citations recorded by the source corpus.
The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth and metabolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as cancer, diabetes, obesity, neurological diseases and genetic disorders. Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and the potential utility of combination therapy with rapamycin.
Subfields: Molecular Biology, Physiology
View Paper: https://www.semanticscholar.org/paper/7681258cc6d0b5dbea5aae47e8daa9f8bcdd6042
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Physiology
Citations in the corpus
- Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates (2015, background): “While mTOR inhibitors have been proposed as general anti-cancer agents due to the requirement of mTOR signaling for cell growth in most tumor settings, it is notable that mTOR inhibitors are largely cytostatic in clinical use (Li et al., 2014).”
- Cellular Senescence: A Translational Perspective (2017, background): “…impairment, and immune dysfunction in mouse models, and enhance antibody response to influenza vaccination in elderly humans, among other effects (Harrison et al., 2009; Li et al., 2014; Majumder et al., 2012; Wilkinson et al., 2012, Zhang et al., 2014, Mannick et al., 2014; Bitto et al., 2016).”
- mTOR: a pharmacologic target for autophagy regulation. (2015, neutral): “83– 86 ).”